KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine

Abstract Seven viruses cause at least 15% of the total cancer burden. Viral cancers have been described as the “low-hanging fruit” that can be potentially prevented or treated by new vaccines that would alter the course of global human cancer. Kaposi sarcoma herpesvirus (KSHV or HHV8) is the sole ca...

Full description

Bibliographic Details
Main Authors: Corey Casper, Lawrence Corey, Jeffrey I. Cohen, Blossom Damania, Anne A. Gershon, David C. Kaslow, Laurie T. Krug, Jeffrey Martin, Sam M. Mbulaiteye, Edward S. Mocarski, Patrick S. Moore, Javier Gordon Ogembo, Warren Phipps, Denise Whitby, Charles Wood
Format: Article
Language:English
Published: Nature Portfolio 2022-09-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-022-00535-4
Description
Summary:Abstract Seven viruses cause at least 15% of the total cancer burden. Viral cancers have been described as the “low-hanging fruit” that can be potentially prevented or treated by new vaccines that would alter the course of global human cancer. Kaposi sarcoma herpesvirus (KSHV or HHV8) is the sole cause of Kaposi sarcoma, which primarily afflicts resource-poor and socially marginalized populations. This review summarizes a recent NIH-sponsored workshop’s findings on the epidemiology and biology of KSHV as an overlooked but potentially vaccine-preventable infection. The unique epidemiology of this virus provides opportunities to prevent its cancers if an effective, inexpensive, and well-tolerated vaccine can be developed and delivered.
ISSN:2059-0105